clinical trial · NCT07161011
Phase 2b Controlled Study of Dosing Techniques - Part B
Dry EyeIVW-1001 Ophthalmic Eyelid Wipe 0.2%IVW-1001 Ophthalmic Eyelid Wipe 0.4%
brief summary
Double-masked, dose-response of two concentrations of IVW-1001
started
Sep 8, 2025
primary completion
Nov 3, 2025
completion
Nov 3, 2025
last updated
Mar 27, 2026
detailed description
Using the best dosing technique from Study NCT07140380, subjects will be randomized to one of two concentrations.
official title
Phase 2b, Proof-of-Concept, Single-center, Double-Masked, Randomized Study Comparing the Safety, Tolerability, and Efficacy of Three Different Ophthalmic Eyelid Wipe Dosing Techniques Using IVW-1001 in Subjects With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol